Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 01, 2015 1:31 AM ET


Company Overview of Sandoz Inc.

Company Overview

Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...

100 College Road West

Princeton, NJ 08540

United States

Founded in 1946





Key Executives for Sandoz Inc.

President and Head of North America
Chief Financial Officer, Head of Finance - North America and Vice President
President of Oriel Therapeutics
Vice President of Legal, IP & Compliance and General Counsel of NA
Head of Global Development Biopharmaceuticals & Oncology Injectables
Age: 62
Compensation as of Fiscal Year 2015.

Sandoz Inc. Key Developments

Sandoz Introduces Generic Version of Asthma Drug in US

Sandoz Inc. has introduced budesonide inhalation suspension, a generic version of Pulmicort Respules, or budesonide, inhalation suspension 1mg strength, indicated for the treatment of asthma, in the US. Sandoz's budesonide inhalation suspension product is indicated for maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide inhalation suspension is not indicated for the relief of acute bronchospasm.

The Medicines Company Announces Distribution Agreement with Sandoz in US

The Medicines Company has signed an agreement with Sandoz Inc. for the distribution of an authorized generic of its anticoagulant, ANGIOMAX, or bivalirudin, for injection, in the US. This agreement with Sandoz, itself a leader in the generics market, helps to ensure that bivalirudin remains a high quality product in this market.

The Medicines Co. Announces Distribution Agreement with Sandoz Inc

The Medicines Co. announced an agreement with Sandoz Inc. for the distribution of an authorized generic of Angiomax (bivalirudin) for injection in the U.S. Angiomax is indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of GPI and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. Also, Angiomax is indicated for use as an anticoagulant in patients with UA undergoing percutaneous transluminal coronary angioplasty.

Similar Private Companies By Industry

Company Name Region
Cornerstone BioPharma Holdings, Inc. United States
Janssen Ortho LLC United States
Companion Pharma, Inc. United States
Warrior Management, LLC United States
Advion Bioanalytical Labs, Inc. United States

Recent Private Companies Transactions

Private Placement
June 26, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sandoz Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at